Cytotoxicity-Hepatotoxicity Screen DILItrain™

Cytotoxicity-Hepatotoxicity Screen DILItrain™2022-07-12T09:54:07-05:00

Hepatotoxicity Screen (DILItrain™)

Our cytotoxicity and hepatotoxicity screening service makes early, high-acuity assessment of hepatotoxic risk cost-effective and thereby brings new illumination to the challenge of reducing late-stage candidate attrition.  The cytotoxicity and hepatotoxicity results are generated on HUREL® micro livers, which in peer-reviewed studies have been shown to provide predictive sensitivity and accuracy superior to that of both 3D spheroidal primary hepatocyte cultures and hepatoma cell lines.


14-day repeat-dosing protocol with ATP readout on Days 2 and 14.

Study Turnaround Time

Receipt of sample to data delivery, is 21 days


Early lead selection stage of preclinical discovery/development—i.e., at roughly the same time as such other basic panels as solubility and Herg assays—so as to minimize the production burden on synthetic chemistry.


This website uses cookies to enhance the user experience. Ok